Glyceraldehyde-Derived Pyridinium Evokes Renal Tubular Cell Damage via RAGE Interaction

Ami Sotokawauchi 1, Nobutaka Nakamura 1, Takanori Matsui 1, Yuichiro Higashimoto 2* and Sho-ichi Yamagishi 3,*

1 Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume 830-0011, Japan; sotokawauchi_ami@med.kurume-u.ac.jp (A.S.); k9389438@kadai.jp (N.N.); matsui_takanori@med.kurume-u.ac.jp (T.M.)
2 Department of Chemistry, Kurume University School of Medicine, Kurume 830-0011, Japan; higashiy@med.kurume-u.ac.jp
3 Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Showa University School of Medicine, Tokyo 142-8666, Japan
* Correspondence: shoichi@med.showa-u.ac.jp; Tel.: +81-3-3784-8693; Fax: +81-3-3784-8948

Received: 2 March 2020; Accepted: 8 April 2020; Published: 9 April 2020

Abstract: Glyceraldehyde-derived advanced glycation end products (glycer-AGEs) contribute to proximal tubulopathy in diabetes. However, what glycer-AGE structure could evoke tubular cell damage remains unknown. We first examined if deleterious effects of glycer-AGEs on reactive oxygen species (ROS) generation in proximal tubular cells were blocked by DNA-aptamer that could bind to glyceraldehyde-derived pyridinium (GLAP) (GLAP-aptamer), and then investigated whether and how GLAP caused proximal tubular cell injury. GLAP-aptamer and AGE-aptamer raised against glycer-AGEs were prepared using a systemic evolution of ligands by exponential enrichment. The binding affinity of GLAP-aptamer to glycer-AGEs was measured with a bio-layer interferometry. ROS generation was evaluated using fluorescent probes. Gene expression was analyzed by reverse transcription-polymerase chain reaction (RT-PCR). GLAP-aptamer bound to glycer-AGEs with a dissociation constant of 7.7 × 10^{-5} M. GLAP-aptamer, glycer-AGE-aptamer, or antibodies directed against receptor for glycer-AGEs (RAGE) completely prevented glycer-AGE- or GLAP-induced increase in ROS generation, MCP-1, PAI-1, or RAGE gene expression in tubular cells. Our present results suggest that GLAP is one of the structurally distinct glycer-AGEs, which may mediate oxidative stress and inflammatory reactions in glycer-AGE-exposed tubular cells. Blockade of the interaction of GLAP-RAGE by GLAP-aptamer may be a therapeutic target for proximal tubulopathy in diabetic nephropathy.

Keywords: GLAP; RAGE; diabetic nephropathy; proximal tubular cells

1. Introduction

According to the Diabetes Atlas, 9th edition, 2019, an estimated 463 million people worldwide have diabetes, which is an increasing global health burden [1]. Among various complications, diabetic nephropathy is the most common and leading cause of end-stage renal disease, which is associated with the increased risk of cardiovascular disease and total mortality in both type 1 and type 2 diabetic patients [2]. Although strict blood glucose control and management of hypertension with inhibitors of renin-angiotensin system have been shown to significantly reduce the development and progression of diabetic nephropathy, these therapeutic options are far from satisfactory because a substantial population of diabetic patients still develop renal failure [2]. Therefore, identification of residual risk factors is needed for the management of diabetic nephropathy.
We have previously found that DNA-aptamer raised against glyceraldehyde-derived advanced glycation end products (glycer-AGEs), whose formation and accumulation are enhanced in patients with insulin resistance and/or diabetes [2–4], attenuate the progression of renal damage in obese type 2 diabetic mice, thus suggesting that glycer-AGEs may be a novel therapeutic target for diabetic nephropathy [5]. Furthermore, glycer-AGEs have also been shown to evoke oxidative stress generation, inflammatory, and fibrotic reactions in human renal proximal tubular cells via the interaction with receptor for AGEs (RAGE) [6]. These observations suggest that interaction of glycer-AGEs with RAGE may play a role in proximal tubulopathy, a key mover of diabetic nephropathy [7]. However, it remains unclear what structurally distinct glycer-AGEs are involved in diabetic nephropathy. Although modification of proteins by glyceraldehyde could generate a large number of AGEs, including glyceraldehyde-derived pyridinium (GLAP), methylglyoxal-derived hydroimidazolone 1, and argpyrimidine [8–11], GLAP has been identified as one of the major glycer-AGEs existed in diabetic animals or patients [9,12]. Furthermore, we have found that GLAP at 1-10 µg/mL, whose concentrations are comparable with those of the in vivo-diabetic situation, elicits oxidative stress and inflammatory and thrombogenic reactions in endothelial cells through the interaction with RAGE [12]. Therefore, we examined here whether deleterious effects of glycer-AGEs on reactive oxygen species (ROS) generation in proximal tubular cells were blocked by DNA-aptamer that could bind to GLAP (GLAP-aptamer), and then investigated whether and how GLAP caused proximal tubular cell damage in vitro.

2. Results

We first examined the effects of GLAP-aptamer on ROS generation in glycer-AGE-exposed proximal tubular cells. As shown in Figure 1a, compared with non-glycated control bovine serum albumin (BSA), glycer-AGEs significantly increased ROS generation in tubular cells, which was completely blocked by 10 nM GLAP-aptamer, 10 nM DNA-aptamer raised against glycer-AGEs (AGE-aptamer), or 5 µg/mL neutralizing rabbit polyclonal antibody directed against RAGE (RAGE-Ab). Bio-layer interferometry analysis revealed that GLAP-aptamer bound to immobilized glycer-AGEs with a dissociation constant (K_D) of 7.7 × 10^{-3} M (Figure 1b).

![Figure 1](image-url) (a) Effects of RAGE-Ab, AGE-aptamer (AGE-apt), or GLAP-aptamer (GLAP-apt) on reactive oxygen species (ROS) generation in glycer-AGE-exposed tubular cells. Tubular cells were treated with 100 µg/mL glycer-AGEs or 100 µg/mL non-glycated bovine serum albumin (BSA) in the presence or absence of 5 µg/mL RAGE-Ab, 10 nM AGE-apt, or 10 nM GLAP-apt for 1 h. ROS generation was evaluated by CellRox oxidative stress reagents. N = 6–12 per group. # and ##, p < 0.05 and p < 0.01 compared to the values with 100 µg/mL glycer-AGEs. (b) The interaction of GLAP-aptamer to immobilized glycer-AGEs was analyzed by bio-layer interferometry. N = 4 per group.
We next investigated the effects of GLAP on proximal tubular cells. As shown in Figure 2a, GLAP dose-dependently increased ROS generation in tubular cells; 10 µg/mL and 100 µg/mL GLAP increased the ROS generation by 1.3- and 1.6-fold of control values, respectively. Furthermore, 10 nM GLAP-aptamer, 10 nM AGE-aptamer, or 5 µg/mL RAGE-Ab completely blocked the 10 µg/mL GLAP-induced increase in ROS generation in tubular cells (Figure 2b). While 10 nM AGE-aptamer or 5 µg/mL RAGE-Ab alone did not affect the ROS generation in tubular cells, 10 nM GLAP-aptamer alone modestly increased the ROS generation (Figure 2b).

**Figure 2.** Effects of glyceraldehyde-derived pyridinium (GLAP) or GLAP-aptamer (GLAP-apt) on ROS generation (a,b), MCP-1 (c), PAI-1 (d), and RAGE mRNA levels (e) in proximal tubular cells. Tubular cells were treated with the indicated concentrations of GLAP in the presence or absence of 5 µg/mL RAGE-Ab, 10 nM AGE-aptamer (AGE-apt), or 10nM GLAP-apt for 1 h (a,b) or for 4 h (c–e). ROS generation was evaluated by CellRox oxidative stress reagents. N = 6 per group (c–e). Total RNAs were transcribed and amplified by real-time PCR. Data were normalized by the intensity of 18S rRNA mRNA-derived signals and then related to the control values. (c,d) N = 3 per group. (e) N = 7 per group. **, p < 0.01 compared to the control values. # and ##, p < 0.05 and p < 0.01 compared to the values with 10 µg/mL GLAP alone, respectively.
As shown in Figure 2c–e, 10 µg/mL GLAP significantly increased monocyte chemoattractant protein-1 (MCP-1), plasminogen activator inhibitor-1 (PAI-1), and RAGE mRNA levels in tubular cells, which were completely prevented by the treatment with 10 nM GLAP-aptamer, 10 nM AGE-aptamer or 5 µg/mL RAGE-Ab. Ten nM GLAP-aptamer, 10 nM AGE-aptamer or 5 µg/mL RAGE-Ab alone did not affect gene expressions of MCP-1, PAI-1, or RAGE.

3. Discussion

We have previously shown that (1) engagement of RAGE with glycer-AGEs evokes inflammatory, thrombogenic, and fibrotic reactions in human renal proximal tubular cells via ROS generation, (2) sodium-glucose cotransporter 2 (SGLT2)-mediated, high glucose-induced ROS generation augments the glycer-AGE-induced apoptotic cell death of proximal tubular cells via RAGE induction, and (3) inhibitors of SGLT2, such as empagliflozin and tofogliflozin, protect against proximal tubular injury in diabetic animals through its anti-oxidative, anti-inflammatory and anti-fibrotic properties via inhibition of the glycer-AGE-RAGE axis [6,13–16]. Furthermore, recently, high glucose or AGEs have been shown to promote human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition via oxidative stress generation, all of which were ameliorated by empagliflozin [17]. In addition, an SGLT2 inhibitor, dapagliflozin, inhibited the high glucose-induced inflammatory and fibrotic reactions in human proximal tubular epithelial cells by suppressing the RAGE-downstream signaling pathway [18]. These observations indicate that ROS evoked by glycer-AGE-RAGE interaction in the diabetic kidneys may be a therapeutic target for proximal tubulopathy, a more important prognostic factor than glomerulopathy in terms of renal prognosis in diabetic nephropathy [7].

In this study, we found for the first time that (1) like AGE-aptamer or RAGE-Ab, GLAP-aptamer completely prevented the glycer-AGE-induced increase in ROS generation in proximal tubular cells and (2) GLAP-aptamer bound to glycer-AGEs although its binding affinity was relatively weaker than that of AGE-aptamer \( (K_D = 1.4 \times 10^{-6} \text{ M}) \) [5]. These findings demonstrate that GLAP is actually formed in the process of non-enzymatic glycation of BSA by glyceraldehyde in vitro, thus suggesting that GLAP-aptamer may suppress the ROS generation in glycer-AGE-exposed tubular cells by blocking the GLAP-RAGE interaction.

To further examine the clinical relevance of GLAP in proximal tubular cell damage in diabetic nephropathy, we next investigated whether 10 µg/mL GLAP, which concentration is comparable with that of in vivo-diabetic situations [12], could cause proximal tubular cell injury. As with the case of glycer-AGE-exposed cells, we found that 10 µg/mL GLAP significantly stimulated oxidative stress generation and increased MCP-1 and PAI-1 mRNA levels in proximal tubular cells, all of which were completely blocked by RAGE-Ab, AGE-aptamer, or GLAP-aptamer. These observations indicate that GLAP could elicit oxidative stress generation and inflammatory reactions in proximal tubular cells via the interaction with RAGE. We have previously shown that AGE-aptamer binds to GLAP with \( K_D \) of \( 3.3 \times 10^{-5} \text{ M} \) and inhibits the GLAP-induced endothelial cell damage [12]. Therefore, AGE-aptamer may exert protective effects against experimental diabetic nephropathy in obese type 2 diabetic mice partly by blocking the interaction of GLAP with RAGE [5,12].

In the present study, RAGE-Ab completely prevented the up-regulation of RAGE mRNA levels in GLAP-exposed tubular cells. Given the facts that MCP-1 and PAI-1 contribute to tubulointerstitial injury and fibrosis in diabetic nephropathy [6,19–21], GLAP-RAGE interaction-mediated RAGE gene induction might make a vicious cycle, thereby further potentiating tubular cell damage in diabetic nephropathy. Taken together, our present findings suggest that GLAP is one of the structurally distinct glycer-AGEs, which may mediate oxidative stress generation, inflammatory and fibrotic reactions in glycer-AGE-exposed proximal tubular cells. Since the results of this study were based on experiments performed on a single cell line, an animal model experiment is needed to examine whether GLAP-aptamer may be a novel therapeutic tool for proximal tubulopathy in diabetic nephropathy. Furthermore, although the present findings suggest that among the different structurally identified AGEs, GLAP was a major AGE that could mediate the deleterious effects of glycer-AGEs, it would be
interesting to test the effects of other glycer-AGEs, such as methylglyoxal-derived hydroimidazolone 1 and argpyrimidine on proximal tubular cells using the same protocol as the one used for GLAP.

4. Materials and Methods

Glycer-AGEs and non-glycated control BSA were prepared as described previously [12]. In brief, BSA was incubated under sterile conditions with or without glyceraldehyde for 7 days. Then, unbound sugars were removed by dialysis against phosphate-buffered saline. GLAP was synthesized by incubating N-acetyl-L-lysine with glyceraldehyde for 7 days [12]. GLAP was synthesized according to the method of Usui et al. [9,12]. In brief, glyceraldehyde (0.2 M) and N-acetyl-L-lysine (0.1 M) were dissolved in 0.2 M sodium phosphate buffer (pH 7.4), and incubated at 37 °C. After a week, the reaction mixture was filtered, and then put on a C8 column on preparative reverse phase high-performance liquid chromatography [9]. Sections of AGE-aptamer and GLAP-aptamer were performed using systemic evolution of ligands by exponential enrichment; sequences of AGE-aptamer and GLAP-aptamer were 5′-tgTAgcccgAgTATcTccATcgccccAgATacAAg-3′ and 5′- gcGggTtgGgaGccActAgtAgcAacGtgCgaCccTctAcgAagCaaAccAtcCtcA-3′, where 5′ side of phosphorothioate nucleotides are indicated as capital letters [12]. RAGE-Ab, which recognizes the amino acid residues 167-180 of human RAGE, was prepared as described previously [12]. The interaction of GLAP-aptamer to immobilized glycer-AGEs on the biosensor tip surface was analyzed by bio-layer interferometry using a BLItz instrument (ForteBio, Inc., Menlo Park, CA, USA).

Human primary cultured renal proximal tubular epithelial cells were obtained from Lonza Group Ltd. (Basel, Switzerland) and maintained in basal medium containing 0.5% fetal bovine serum according to the supplier’s instructions [12]. Cell experiments were carried out in a serum-free basal medium. Tubular cells were treated with 100 µg/mL glycer-AGEs, 100 µg/mL non-glycated BSA, or the indicated concentrations of GLAP in the presence or absence of 5 µg/mL RAGE-Ab, 10 nM AGE-aptamer, or 10 nM GLAP-aptamer for 1 h (ROS generation assay) or for 4 h (real-time reverse transcription-polymerase chain reaction (RT-PCR) analysis). ROS generation was evaluated by CellRox oxidative stress reagents (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s recommendation [22]. Total RNA was extracted with NucleoSpin RNA kit (Takara Bio Inc., Shiga, Japan) according to the manufacturer’s instructions. Quantitative real-time RT-PCR was performed using Assay-on-Demand and TaqMan 5 fluorogenic nuclease chemistry (Life Technologies Japan Ltd., Tokyo, Japan). Gene expressions of MCP-1, PAI-1, and RAGE were evaluated by RT-PCR analyses; IDs of primers for MCP-1, PAI-1, RAGE, and 18S rRNA gene were Hs00234140_m1, Hs01126606_m1, Hs00542592_g1, and Hs9999901_s1, respectively [8].

All values were presented as mean ± standard deviation. One-way ANOVA followed by Dunnett’s test for Figure 2a or student’s t-test for rest of all were performed for statistical comparisons; p < 0.05 was considered significant.

5. Conclusions

Our present results suggest that GLAP is one of the structurally distinct glycer-AGEs, which may mediate oxidative stress and inflammatory reactions in glycer-AGE-exposed tubular cells. Blockade of the interaction of GLAP-RAGE by GLAP-aptamer may be a therapeutic target for proximal tubulopathy in diabetic nephropathy.

Author Contributions: S.-i.Y. conceptualized and designed the study; acquired, analyzed, and interpreted the data; and drafted the manuscript; and he takes responsibility for the integrity of the data and accuracy of data analysis. A.S., N.N., T.M., and Y.H. acquired, analyzed, and interpreted the data. All authors have read and agree to the published version of manuscript.

Funding: This work was supported in part by Grants-in-Aid for Scientific Research (Grant Number 17K08968) (SY) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References
1. IDF Diabetes Atlas-9th Edition. Available online: https://www.diabetesatlas.org/en/ (accessed on 6 April 2020).
2. Yamagishi, S.I.; Nakamura, N.; Matsui, T. Glycation and cardiovascular disease in diabetes: A perspective on the concept of metabolic memory. J. Diabetes. 2017, 9, 141–148. [CrossRef] [PubMed]
3. Yamagishi, S.; Nakamura, N.; Sueyama, M.; Kaseda, K.; Matsui, T. Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes. Mol. Mol. 2015, 21, S32–S40. [CrossRef] [PubMed]
4. Tahara, N.; Yamagishi, S.; Matsui, T.; Takeuchi, M.; Nitta, Y.; Kodama, N.; Mizoguchi, M.; Imaiizu, T. Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects. Cardiovasc. Ther. 2012, 30, 42–48. [CrossRef] [PubMed]
5. Kaida, Y.; Fukami, K.; Matsui, T.; Higashimoto, Y.; Nishino, Y.; Obara, N.; Nakayama, Y.; Ando, R.; Toyonaga, M.; Ueda, S.; et al. DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy. Diabetes 2013, 62, 3241–3250. [CrossRef]
6. Matsui, T.; Yamagishi, S.; Takeuchi, M.; Ueda, S.; Fukami, K.; Okuda, S. Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. Pharmaco. Res. 2010, 61, 34–39. [CrossRef]
7. Gilbert, R.E. Proximal Tubulopathy: Prime Mover and Key Therapeutic Target in Diabetic Kidney Disease. Diabetes 2017, 66, 791–800. [CrossRef]
8. Tahara, N.; Yamagishi, S.; Takeuchi, M.; Honda, A.; Tahara, A.; Nitta, Y.; Kodama, N.; Mizoguchi, M.; Kaida, H.; Ishibashi, M.; et al. Positive association between serum level of glyceraldehyde-derived advanced glycation end products and vascular inflammation evaluated by [(18)F]fluorodeoxyglucose positron emission tomography. Diabetes Care 2012, 35, 2618–2625. [CrossRef]
9. Usui, T.; Shimohira, K.; Watanabe, H.; Hayase, F. Detection and determination of glyceraldehyde-derived pyridinium-type advanced glycation end product in streptozotocin-induced diabetic rats. Biosci. Biotechnol. Biochem. 2007, 71, 442–448. [CrossRef]
10. Usui, T.; Watanabe, H.; Hayase, F. Isolation and identification of 5-methyl-imidazolin-4-one derivative as glyceraldehyde-derived advanced glycation end product. Biosci. Biotechnol. Biochem. 2006, 70, 1496–1498. [CrossRef]
11. Usui, T.; Ohguchi, M.; Watanabe, H.; Hayase, F. The formation of argyrymidine in glyceraldehyde-related glycation. Biosci. Biotechnol. Biochem. 2008, 72, 568–571. [CrossRef]
12. Matsui, T.; Oda, E.; Higashimoto, Y.; Yamagishi, S. Glyceraldehyde-derived pyridinium (GLAP) evokes oxidative stress and inflammatory and thrombogenic reactions in endothelial cells via the interaction with RAGE. Cardiovasc. Diabetol. 2015, 14, 1. [CrossRef] [PubMed]
13. Maeda, S.; Matsui, T.; Takeuchi, M.; Yamagishi, S. Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis. Diabetes Metab. Res. Rev. 2013, 29, 406–412. [CrossRef] [PubMed]
14. Ojima, A.; Matsui, T.; Nishino, Y.; Nakamura, N.; Yamagishi, S. Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis. Horm. Metab. Res. 2015, 47, 686–692. [CrossRef] [PubMed]
15. Ishibashi, Y.; Matsui, T.; Yamagishi, S.I. Tofogliflozin, A Highly Selective Inhibitor of SGLT2 Blocks Proinflammatory and Proapoptotic Effects of Glucose Overload on Proximal Tubular Cells Partly by Suppressing Oxidative Stress Generation. Horm. Metab. Res. 2016, 48, 191–195. [CrossRef]
16. Ishibashi, Y.; Matsui, T.; Yamagishi, S.I. Togofliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAY/Ta mice, obese and type 2 diabetic animals. Diab. Vasc. Dis. Res. 2016, 13, 438–441. [CrossRef]
17. Das, N.A.; Carpenter, A.J.; Belenchia, A.; Aroor, A.R.; Noda, M.; Siebenlist, U.; Chandrasekar, B.; DeMarco, V.G. Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition. *Cell Signal.* 2020, 68, 109506. [CrossRef]

18. Yao, D.; Wang, S.; Wang, M.; Lu, W. Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1-receptor for advanced glycation end products-nuclear factor-κB signaling pathway. *Mol. Med. Rep.* 2018, 18, 3625–3630. [CrossRef]

19. Lassila, M.; Fukami, K.; Jandeleit-Dahm, K.; Semple, T.; Carmeliet, P.; Cooper, M.E.; Kitching, A.R. Plasminogen activator inhibitor-1 production is pathogenetic in experimental murine diabetic renal disease. *Diabetologia* 2007, 50, 1315–1326. [CrossRef]

20. Yiu, W.H.; Wong, D.W.; Wu, H.J.; Li, R.X.; Yam, I.; Chan, L.Y.; Leung, J.C.; Ian, H.Y.; Lai, K.N.; Tang, S.C. Kallistatin protects against diabetic nephropathy in db/db mice by suppressing AGE-RAGE-induced oxidative stress. *Kidney Int.* 2016, 89, 386–398. [CrossRef]

21. Sharma, I.; Tupe, R.S.; Wallner, A.K.; Kanwar, Y.S. Contribution of myo-inositol oxygenase in AGE:RAGE-mediated renal tubulointerstitial injury in the context of diabetic nephropathy. *Am. J. Physiol. Renal Physiol.* 2018, 314, F107–F121. [CrossRef]

22. Ishibashi, Y.; Matsui, T.; Nakamura, N.; Sotokawauchi, A.; Higashimoto, Y.; Yamagishi, S.I. Methylglyoxal-derived hydroimidazolone-1 evokes inflammatory reactions in endothelial cells via an interaction with receptor for advanced glycation end products. *Diab. Vasc. Dis. Res.* 2017, 14, 450–453. [CrossRef] [PubMed]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).